Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03946111 · ClinicalTrials.gov registry record · Phase 2
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03946111 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 3 participants.
The verdict
NCT03946111, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will test the relative efficacy and effectiveness of the combination of naltrexone and bupropion (NB) medication as a treatment for binge-eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst non-responders to acute treatments, NB medication results in superior outcomes compared with placebo.
Interventions
- OTHER Placebo
- DRUG Naltrexone and Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03946111
The ClinicalTrials.gov registry entry for NCT03946111 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03946111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03946111 about?
NCT03946111 is a clinical study titled "Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders". This study will test the relative efficacy and effectiveness of the combination of naltrexone and bupropion (NB) medication as a treatment for binge-eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst non-responders to acute treatments, NB medication results...
What is the current status of trial NCT03946111?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-08-07. Estimated completion is 2024-12-05.
What interventions are being tested in trial NCT03946111?
The interventions under investigation include: Placebo (OTHER), Naltrexone and Bupropion (DRUG).
Who is sponsoring clinical trial NCT03946111?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.